drugset / Trial / NCT01429831

Aripiprazole for the Augmentation of Antidepressant Therapy

NCT01429831

Phase 4 Completed 300 enrolled Taiwan Otsuka Pharm. Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

The study aims to evaluate effectiveness and tolerability of aripiprazole augmentation in outpatients with major depressive disorder who have had inadequate response to antidepressants in Taiwan clinical practice.

Timeline

Start
2011-09
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 2 mg
Subject Aripiprazole Other / unclassified 5 mg
Subject Aripiprazole Other / unclassified 15 mg